Chronic obstructive pulmonary disease: Recommendation of salmeterol in fixed combination;Chronisch obstruktive lungenerkrankungen: Salmeterol in fixkombination empfohlen

Deutsche Apotheker Zeitung

Volumn 143, Issue 11, 2003, Pages 48-51

  Bruhn, Claudia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ATMADISC; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL XINAFOATE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; FORCED EXPIRATORY VOLUME; HUMAN; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0037434951     PISSN: 00119857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. Calverley P., et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361, 449-456 (2003).
2. arznei-telegramm: "blitz-a-t" vom 24. Januar 2003: Sicherheitsbedenken: Salmeterol (Serevent®)-Studie gestoppt. A.T.I. Arzneimittelinformation Berlin GmbH.
3. Study of asthma-drug halted. FDA Talk Paper, 23, Januar 2003: U.S. Food and Drug Administration.
4. Safety Alert - Serevent® (salmeterol xinafoate): MedWatch - The FDA safety information and adverse event reporting program, www.fda.gov.